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Comments to Authors:
1. Methods: a) Do you think that the retrospective measurement of all markers in the blood samples could bias the results? Where and how did you preserve the samples? b) When you are talking about MESI, do you include the non-occlusive type? How did you recognise NOMI? Have you performed a CT before laparotomy and if yes, could you provide more information about the etiology of the MESI? c) Statistical analysis: I can imagine that you used Wilcoxon in case of samples coming from the same patient. Which test was used when you compared patients with lapartomy with and without MESI? 2. Results: a) Please provide the rates always (e.g. 18/567: 3%) b) How many of those patients developing MESI or with the clinical suspicion of MESI were treated on CPB? Moreover, what kind of operations were performed and did you observe any intraoperative complications or prolonged op time in this group? c) Could you provide any comparisons between patients with NOMI or non-NOMI? d) How did you treat the patients with MESI? e) Could you provide a table with the type of operations in patients with laparotomy? 3) Discussion: a) Are these outcomes going to change sth in your daily practice? b) Why should you perform a laparotomy and not a laparoscopy first? 4. General comments:
A) The topic of your research is very important and interesting. However, the presentation of the cohort is a little bit difficult. You have to explain the type of MESI; if all cases were NOMI, then you have to change the terminology. B) Try to determine if there was a correlation between type of operation, op time and ICU stay with the need of laparatomy or MESI. By this way, you can recommend that in these types of patients (e.g. patient after mitral valve replacement with op duration > 4h, and ICU stay > 2 days) you have to check these markes. This would be very helpful for the readers. C) You are talking about early diagnosis but it seems that this will not influence the outcome according to the literature in case of NOMI. Did I understand it right? In this case, you have to discuss the real benefit of early detection. However, the quality of data acquisition is poor and the paper has several major flaws: -there was a similar study published by Ludewig et al. in 2017. Why was this study not cited or the results discussed since they are completely different to the results of the presented study? -how was the decision for performing a laparotomy made? CT-based? Clinical state? -the number of patients is too low to draw a significant conclusion. Only 1,5 % of the observed patients received a laparotomy, the study design seems to be a random shot.
Reviewer 2: anonymous
-IFABP is mainly produced in the small intestine, but only two patients had a small bowel ischemia. How do the authors interpret this? -How many patients needed a perioperative renal replacement therapy? -How many patients suffered from liver cirrhosis? 4 Please judge the overall scientific quality of the manuscript.
3 Are you willing to review the revision of this manuscript? Yes
Comments to Authors:
This is a nice paper which describes the difficulty of discover a mesenteric ischemia after cardiac surgery. There are no standard clinical markers after surgery. Normally it is a combination of clinical examination an high serum lactat. But lactat after cardiac surgery is often high because of the low cardiac output after cardiac surgery in patients with preoperativ low ejection fraction ( EF). This results in a relative ischemia with higher serum lactat. Most mesenteriac ischemia are non occlusive so diagnostic with CT scan shows the extent of mesenteriac ischemia just in an advaced stage, when a surgery is almost to late. Non occlusive MI is often a result of high catecholamines in patients with low cardiac Output, so it is a circulus vitiosus. The idea of finding markers for MESI is really important and make the decision for a laparotomy in patients after cardiac surgery easier. I would be interested in the number of patients in your study who died because of MI after cardiac surgery and were not presented for surgery?
Authors' Response to Reviewer Comments
Oct 30, 2018 Reviewer#1
Methods:
Question#a: Do you think that the retrospective measurement of all markers in the blood samples could bias the results? Where and how did you preserve the samples?
Answer#a: In fact, the retrospective measurement of the samples could change the actual value. The samples were stored at -80°C after centrifugation and collected the regular laboratory parameters and then measured in larger groups to have sufficient samples for the rather expensive essays. In preliminary experiments with animal samples, the duration of the sample storage had no influence on the measurement result.
If, however, a non-excludable error should have occurred due to the time interval until storage, this would be a systematic error that should not have led to any bias.
Question#b: When you are talking about MESI, do you include the non-occlusive type? How did you recognise NOMI? Have you performed a CT before laparotomy and if yes, could you provide more information about the etiology of the MESI?
Answer#b: In our opinion, mesenteric ischemia (MESI) is the final stage of a mesenteric underperfusion either on the basis of an occlusive or non-occlusive (NOMI) cause. In order to have the hardest possible endpoint, we used the laparatomy and the intraoperative result of this. In 7/18 patients a CT and one angiography was performed before laparotomy, without any evidence of occlusion of an intestinal vessel. In most cases, however, the intestinal vessels were narrow and reduced in perfusion. However, since the CT findings were rarely unambiguous, laparotomy was performed in conjunction with the clinical signs. (We added the sentences: "Indication for laparotomy was primarily given by clinical signs for an acute abdomen, continuous hyperlactatemia or increasing need for vasopressors. Additional CT-imaging without evidence for any occlusive mesenteric malperfusion was performed in 7/18 patients. Angiography was performed in one patient") In all cases, as in cardiosurgical patients typical, MESI was due to a low cardiac output and high catecholamines doses leading to NOMI. As described in the literature, we believe that a NOMI of varying magnitude occurs in almost every patient undergoing cardiac surgery, but can be compensated in most patients, and leads to a final image of MESI in only a few patients.
Question#c: Statistical analysis: I can imagine that you used Wilcoxon in case of samples coming from the same patient. Which test was used when you compared patients with lapartomy with and without MESI?
Answer#c: For statistical analysis of this paper we worked with an professional statistician, who we contacted again. The patient with and without MESI were compared by an simple t-test. This was added to the statistical part (change was marked red)
Results:
Question#a: Please provide the rates always (e.g. 18/567: 3%)
Answer#a: Rates were changed and marked red.
Question#b: How many of those patients developing MESI or with the clinical suspicion of MESI were treated on CPB? Moreover, what kind of operations were performed and did you observe any intraoperative complications or prolonged op time in this group?
Answer#b: In all but one patient with subsequent laparotomy (thoracoabdominal aortic replacement with axillo-femoral bypass) the heart lung machine was used. The types of surgery in the laparotomy group were: two isolated coronary bypass operations, one biological aortic valve replacement, 2 left ventricular assist devices, 3 lung trans pantations, 9 combination procedures, and one thoracoabdominal replacement. The mean Euroscore in this Group was 41.9 ± 11 which was significantly higher compared to the non laparotomoy group (10,5 ± 1, p<0.001).
However, this paper does not aim at the incidence or clinical causes and risk factors of mesenteric ischemia, but at identifying and validating early markers. Therefore, the focus of the analysis was on the markers and not the clinical data.
Question#c: Could you provide any comparisons between patients with NOMI or non-NOMI?
Answer#c: Since we have not proven an occlusive disease in any of the patients, this comparison is unfortunately not possible.
Question#d: How did you treat the patients with MESI?
Answer#d: In addition to the attempt to reduce the necessary catecholamine doses and generate an optimal cardiac output, the treatment Question#a: Are these outcomes going to change sth in your daily practice?
Answer#a: If affordable I would use these markers as very early markers for general hypoperfusion with effect to the mesenterium. In my daily practice today I try to avoid catecholamines as much as possible and early on I set the indication to additional extracorporeal support systems to ensure the best possible perfusion.
Question#b: Why should you perform a laparotomy and not a laparoscopy first?
Answer#b: In fact, a laparotomy to exclude intestinal ischemia would be much more gentle, faster and in doubt even bed-side feasible. During the study period, however, our colleagues in general surgery performed only a few laparoscopic procedures and the argument of not being able to perform resections was put forward. Therefore, all laparotomies were performed openly. Meanwhile, laparoscopies are also performed.
General comments:
Question#A: The topic of your research is very important and interesting. However, the presentation of the cohort is a little bit difficult. You have to explain the type of MESI; if all cases were NOMI, then you have to change the terminology.
Answer#A: As already described in the introduction, the cause of mesenteric ischemia with the final picture of mesenteric necrosis can be manifold. The term NOMI merely describes a possible etiology of mesenteric ischemia. Further causes may be embolic events and thus occlusive mesenteric ischemia, reduced cardiac output or venous congestion. In cardiosurgical patients the events will mostly be multimodal, therefore the classification NOMI and OMI was deliberately avoided but used for a clear classification of the groups MESI in the sense of a safe clinically and pathologically proven mesenteric ischemia.
Question#B: Try to determine if there was a correlation between type of operation, op time and ICU stay with the need of laparatomy or MESI.
By this way, you can recommend that in these types of patients (e.g. patient after mitral valve replacement with op duration > 4h, and ICU stay > 2 days) you have to check these markes. This would be very helpful for the readers.
Answer#B: No differences were found between the groups with and without laparotomy with respect to mean age ( Question#C: You are talking about early diagnosis but it seems that this will not influence the outcome according to the literature in case of NOMI. Did I understand it right? In this case, you have to discuss the real benefit of early detection.
Answer#C: We completely agree. On the other side there is not only black and white. In our understanding and from our experience in rat models we know, that MESI is a dynamic process involving other organs. It seems like any use of CPB or hypotension, even running a marathon, leeds to some degree of mesenteric malperfusion. Depending on the duration and the recovery capacity different degrees of damage occure.
We were looking for markers that could help us to get a deeper understanding of these processes after heart surgery. Therefore, we wrote in the discussion section: "The definition of MESI as intestinal ischemia treated by laparotomy and resection is unambiguous and used in most retrospective studies. However, it does not reflect the dynamics of this disease and its pathomechanism which is non-occlusive (NOMI) in 95% [3] with an incidence after cardiac surgery up to 10% [23]. We assume an even higher rate of mild and non-apparent MESI after most cardiac operations demonstrated by elevated markers after CPB in all studies including ours. Although αGST and D-lactate seem to be suitable markers for early detection of gastrointestinal complications after cardiac surgery and iFABP-2 could help differenciating patients with ischemia, resection of necrotic tissue is only damage control, and the benefit of a very early resection is questionable. Accepting the pathologic mechanism and the dynamic character new therapeutic and protective approaches are required. Substances like Glycine [24, 25] and Pyruvate [26] demonstrated protective effects in MESI models in rats. The evaluated markers could not only be useful for early detection of patients with mesenteric ischemia, but also represent a new routine for evaluation of protective effects of different substances or conditioning maneuvers in further clinical studies."
Reviewer#2
Question#1: Do you think that the retrospective measurement of all markers in the blood samples could bias the results? Where and how did you preserve the samples? Answer#1: This manuskript was mainly written with one interruption for an international fellowship before the Ludewig paper was published, therefore it was not recognized and cited. However, the authors explain thereselves: "It may be possible that I-FABP is not released when the ischemia of the bowel wall progresses and the mucosa does not recover, leading to false negative I-FABP test results". In our study only patients with proven bowel necrosis were categorized as MESI patients and therefore they might have no more I-FABP to release as stated in our discussion. On the other hand nearly our complete control group underwent cardiopulmonary bypass before the first postoperative measurement. Based on the high sensitivity of the marker we can expect elevated markers in nearly all patients, even in the control group, except those that have really severe damage, that does only recover within the next days.
Question#2: How was the decision for performing a laparotomy made? CT-based? Clinical state?
Answer#2: In 7/18 patients a CT and one angiography was performed before laparotomy, without any evidence of occlusion of an intestinal vessel. In most cases, however, the intestinal vessels were narrow and reduced in perfusion. However, since the CT findings were rarely unambiguous, laparotomy was performed in conjunction with the clinical signs. (We added the sentences: "Indication for laparotomy was primarily given by clinical signs for an acute abdomen, continuous hyperlactatemia or increasing need for vasopressors. Additional CT-imaging without evidence for any occlusive mesenteric malperfusion was performed in 7/18 patients. Angiography was performed in one patient") Question#3: The number of patients is too low to draw a significant conclusion. Only 1,5 % of the observed patients received a laparotomy, the study design seems to be a random shot.
Answer#3: The study cohort includes 567 patients. Serum samples 1, 24 and 48h after cardiac surgery of 510 (90%), 502 (89%), and 313 (55%) patients respectively and 18 patients up to 72h before laparotomy were analysed. Basically we compared the markers of 18 patients with laparotomy with 510 patients without. The group of laparotomy patients (3.6%) looks small but the effect must have been strong enough, so that the differences were statistically significant. The study presented here was planned following a pilot study. As part of the pilot study, we collected blood samples from patients suspected of having mesenteric ischemia who were laparotomized shortly afterwards. To our surprise, the measured values at this time shortly before the laparotomy were significantly lower than expected. On the other hand, the values measured early postoperatively as a control group were higher. We concluded from this that probably every use of the HLM causes a mesenteric ischemia of small magnitude and that the release of markers is no longer to be expected if the tissue is already in a position to measure as many meaningful samples as possible with the limited financial resources, we decided on the selected study design, in which we first observe the early postoperative markers and the early postoperative course of all patients and in patients who undergo a laparotomy also the period before the laparotomy. This procedure seemed to us to be reasonable and was no coincidence. Retrospectively, we should also have taken preoperative samples, but we could not do this after the study.
Question#4: IFABP is mainly produced in the small intestine, but only two patients had a small bowel ischemia. How do the authors interpret this?
Answer#4: We completely agree with you, I-FABP is expressed in a significantly higher proportion in the small intestine. Nevertheless, an expression in the large intestine is also described. Furthermore, the fact that only in 2 patients a resection worthy necrosis of the small intestine was found does not mean that in the remaining patients with a resection of the large intestine not also an intraluminal but not a transmural damage of the small intestine is present.
Question#5: How many patients needed a perioperative renal replacement therapy?
Answer#5: Out of the total cohort 82.5% needed no postoperative renal replacement therapy, 15% received temporary postoperative renal replacement therapy, 2.5% needed intermittend dialysis postoperatively. Temporary postoperative dialysis therapy was significantly more frequent in patients that needed a laparotomy during the postoperative course (33% vs 14.4% p<0.001). We do not know how many of the patients had intraoperative dialysis, but agree that CVVHD intra-and postoperatively, as well as the renal function might have influenced the FABP values. We were unfortunately unable to exclude this variable.
Question#6: How many patients suffered from liver cirrhosis?
Answer#6: We did not store any information about the liver function, but agree, that it might have influenced the markers as well.
Reviewer#3
Question#1: I would be interested in the number of patients in your study who died because of MI after cardiac surgery and were not presented
